HIV-1 envelope-specific T cell receptor (HIV-1 Env-specific TCR) (HIV-1 Env-specific TCR)

HIV-1 envelope-specific T cell receptors (TCRs) are specialized immune receptors that recognize peptides derived from the HIV-1 envelope glycoproteins (gp120 and gp41) when presented by Major Histocompatibility Complex (MHC) molecules. These TCRs are a primary focus in the development of adoptive T cell therapies, where a patient's own T cells are genetically modified to express high-affinity TCRs targeting viral antigens [Kitchen et al., 2011]. Upon recognition of the peptide-MHC complex on an infected cell, the TCR triggers a signaling cascade that leads to T cell activation, proliferation, and the release of cytotoxic molecules like perforin and granzymes to eliminate the infected cell [Hale et al., 2017]. This therapeutic strategy is designed to target the latent HIV-1 reservoir that remains inaccessible to standard antiretroviral therapy. However, the high mutation rate of the HIV-1 envelope protein often leads to the emergence of escape mutants that the TCR can no longer recognize. Additionally, ensuring that the engineered TCR does not cross-react with host proteins is a critical safety requirement for clinical application [VRC/NIH, 2020]. The efficacy of these TCRs is also limited by the ability of HIV-1 to downregulate MHC molecules, thereby hiding from T cell detection. Despite these challenges, TCR-based therapies represent a promising avenue for achieving a functional cure for HIV-1 infection.

Other names

HIV-1 Env-specific TCRTCR recognizing HIV-1 Env/MHCHIV-1 envelope-reactive T-cell receptorgp120-specific TCRgp41-specific TCR

Engineered T cells expressing these TCRs recognize HIV-1 envelope peptides presented by MHC class I molecules on the surface of infected cells, triggering T cell activation and the subsequent lysis of the target cell [Kitchen et al., 2011].